According to a report by Intel Market Research, the global Tenofovir Disoproxil Fumarate API Market was valued at USD 329.0 million in 2025 and is estimated to reach USD 342.0 million in 2026. The market is projected to reach USD 480.0 million by 2034, representing a 4.33% CAGR during 2026–2034. Tenofovir disoproxil fumarate (TDF) is a high-volume nucleotide reverse transcriptase inhibitor API used in HIV treatment, chronic hepatitis B treatment, and tenofovir-containing oral HIV prevention. Its 300 mg adult dose and broad use across treatment and prevention programs create substantial recurring API requirements.

Explore the full report: Tenofovir Disoproxil Fumarate API Market Report

Why Is Demand Increasing?

• Large-scale HIV treatment programs: The report states that 32.1 million people were accessing antiretroviral therapy in 2025, creating a substantial recurring demand base for tenofovir-containing treatment backbones.

• Chronic hepatitis B treatment: WHO's latest estimate cited in the report places the global chronic hepatitis B population at 254 million, creating a separate long-duration treatment channel for TDF API.

• Oral HIV prevention: Tenofovir-containing oral PrEP remains an established prevention option. The report notes that 3.9 million people used PrEP at least once in 2024, providing incremental demand beyond treatment markets.

HIV, Hepatitis B & Prevention API Industry Watch

The TDF API industry is being shaped by the combination of large HIV treatment volumes, chronic hepatitis B therapy and oral prevention programs. Asia-Pacific leads API manufacturing through a dense Indian and Chinese quality-assured supplier base, while Africa represents the largest downstream HIV-treatment demand pool. The report highlights two new quality-assured sources added in 2026: Styrax Pharma received WHO prequalification in February and SMS Pharmaceuticals in April. Competition extends beyond molecule availability to compaction performance, impurity control, storage stability, regulatory documentation and supply economics. Compacted or particle-engineered TDF is also gaining commercial relevance because improved bulk handling and flow can support large-scale fixed-dose-combination manufacturing. At the same time, aggressive global-health pricing and substitution by tenofovir alafenamide in selected markets moderate unit-value growth.

Segmentation Highlights

• By Type: Standard TDF and Compacted/Particle-Engineered TDF. Standard TDF accounts for the largest volume, while compacted grades provide processing advantages in high-volume fixed-dose combinations.

• By Application: HIV Treatment, Chronic Hepatitis B Treatment, and PrEP/PEP & Prevention. HIV treatment represents the largest demand pool, with hepatitis B and prevention expanding the market's application base.

• By Formulation Destination: 300 mg Single-Agent Tablets; TLD & Other 3TC Combinations; TDF/FTC Combinations; Pediatric/Other Oral Products.

• By Customer Type: Global Health/FPP Manufacturers; Generic Formulation Manufacturers; Branded/Institutional Manufacturers.

• By Procurement Model: Direct Manufacturer Contracts; Global Health/Long-Term Procurement; Captive/Internal Transfer.

• By Regulatory Destination: WHO-Prequalified/Highly Regulated Markets; Emerging & Other Regulated Markets.

Regional Outlook

• Asia-Pacific leads API manufacturing through a broad Indian and Chinese quality-assured supplier base. The report identifies sources from Matrix Pharmacorp, Sun Pharmaceutical Industries, Laurus Labs, Shanghai Desano, Mangalam Drugs, Shijiazhuang Lonzeal, Styrax Pharma and SMS Pharmaceuticals.

• North America has demand across HIV treatment, chronic hepatitis B and oral PrEP, although TAF has captured share in several newer branded regimens. Current U.S. TDF products retain the 300 mg adult tablet strength.

• Europe represents a mature market increasingly segmented between TDF and TAF, with TDF retaining important generic and public-health applications.

• Latin America generates recurring imported TDF demand through HIV treatment and prevention programs, with procurement increasingly favoring low-cost fixed-dose combinations.

• Middle East & Africa contains significant downstream demand. Africa is identified as the largest downstream HIV-treatment pool, while the report cites 64.7 million people in Africa living with chronic hepatitis B in 2022.

Download the free sample report: Free Tenofovir Disoproxil Fumarate API Market Sample

Why This Market Matters

The Tenofovir Disoproxil Fumarate API Market occupies a significant position in global antiviral supply because TDF serves multiple established treatment and prevention applications. Its use in HIV treatment, chronic hepatitis B and oral PrEP creates several recurring demand channels rather than dependence on a single finished-product category. The report also identifies a 300 mg adult tablet strength, which contributes to substantial annual API tonnage when used across large patient populations.

Manufacturing characteristics are equally important. Standard TDF remains the largest-volume segment, while compacted and particle-engineered grades can improve bulk handling, blending and tablet compression in high-volume fixed-dose combinations. Quality-assured supply, WHO prequalification, mature regulatory files, manufacturing scale and supply continuity therefore remain important commercial considerations for API suppliers and finished-dose manufacturers.

Competitive Landscape

• Laurus Labs — Maintains standard and compacted WHO-prequalified TDF grades, providing both scale and downstream processing options.

• Matrix Pharmacorp — Maintains a long-standing WHO-prequalified standard TDF source with current confirmation documentation.

• Styrax Pharma — Added a WHO-prequalified TDF source in February 2026, expanding quality-assured Indian capacity.

• SMS Pharmaceuticals — Received WHO TDF prequalification in April 2026, adding another regulated Indian source.

• Shanghai Desano and other Asian suppliers — Provide additional quality-assured competition across HIV, hepatitis B and prevention markets.

View the full report: Tenofovir Disoproxil Fumarate API Market Report

FAQ

Q: What is the size of the Tenofovir Disoproxil Fumarate API Market?

A: The market was valued at USD 329.0 million in 2025, is estimated at USD 342.0 million in 2026 and is projected to reach USD 480.0 million by 2034, representing a 4.33% CAGR during 2026–2034.

Q: Which region leads the TDF API Market?

A: Asia-Pacific leads API manufacturing because India and China host a broad quality-assured supplier base. Africa represents the largest downstream HIV-treatment demand pool.

Q: Which applications drive TDF API demand?

A: HIV treatment is the largest application, while chronic hepatitis B treatment and oral PrEP/PEP provide additional demand channels.

What Does the Full Report Cover?

The full report examines the Tenofovir Disoproxil Fumarate API Market across six segmentation dimensions: Type, Application, Formulation Destination, Customer Type, Procurement Model and Regulatory Destination. It covers North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa, with analysis of disease burden, manufacturing concentration, procurement structures and regulatory access. The study also explores standard versus compacted TDF grades, HIV treatment, hepatitis B and prevention applications, fixed-dose-combination destinations, quality-assured supplier development and competitive factors such as APIMF depth, impurity control, compaction performance, stability and supply continuity. The report further assesses TAF substitution, global-health pricing pressure, WHO prequalification and market dynamics shaping the forecast through 2034.

View the complete report: Complete Tenofovir Disoproxil Fumarate API Market Report

Download the free sample: Free TDF API Market Sample

About Intel Market Research

Intel Market Research provides quantified market research covering market sizing and forecasting, segmentation, regional analysis, competitive landscapes, regulatory developments and industry trends. The company states that its studies combine primary interviews with structured analysis of named secondary sources, with market estimates validated before publication.

Contact Details

Website: Intel Market Research | Asia-Pacific: +91 9169164321 | Email: help@intelmarketresearch.com